Climb Bio Inc. entered a licensing agreement with Mabworks for developing and commercializing proprietary antibodies, involving an upfront payment of $9 million and potential milestone payments totaling up to $862 million, along with tiered royalties on sales; the company also reported approximately $212.9 million in cash as of December 31, 2024.